The Pathwork Tissue of Origin Test has been extensively evaluated in multiple independent studies involving more than 1,100 patient specimens, including large validation studies published in the Journal of Clinical Oncology and the Journal of Molecular Diagnostics.
A retrospective study of 111 cases from 66 academic and community oncology practices illustrates the use of the test in management of cancer patients. Over two thirds of the cases reviewed showed cancer management changed after the Pathwork Tissue of Origin Test result was received. The majority of the oncologists identified the Tissue of Origin Test results as influencing the decision to make a change in therapy.
Ad Statistics
Times Displayed: 50292
Times Visited: 1434 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
About Pathwork Diagnostics
Pathwork Diagnostics created its proprietary informatics platform to develop and commercialize high-value, medically important diagnostics aimed at helping guide cancer care. Pathwork has commercialized its Pathwork Tissue of Origin product line, and has a robust pipeline and growing portfolio of pharmaceutical partners. Pathwork is privately held and based in Redwood City, CA. For more information call toll-free (877) 808-0006 or visit www.pathworkdx.com.
1. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13.
2. Greco F, Hainsworth J. Introduction: unknown primary cancer. Semin Oncol2009; 36: 6-7.
3. National Comprehensive Cancer Network: NCCN Guidelines on Carcinoma of Unknown Primary. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 2, 2011.
4. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120-124
5. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979. Med PediatrOncol 1982; 10: 569-574.
Ed Stevens
727-327-3396
estevens@pathworkdx.com
Back to HCB News
